RxDoctor Payments Data

Lisa Ferrara, MD

Internal Medicine · West Nyack, NYNPI 1861563736

Payments from drug & device makers

$1,632in general payments, 2019–2025

Across 60 payments — averaging $27.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$409
  • GSK$331
  • Medtronic$160
  • Sumitomo Pharma America, Inc.$145
  • Pfizer$106
  • Astellas Pharma US Inc$80
  • plus $401 from 12 others

What the payments were for

  • Food & beverage$1,632100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,632 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$236,521
Medicare patients
602
Services billed
2,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$30,746
JardianceEmpagliflozin13$22,818
OzempicSemaglutide12$19,184
XareltoRivaroxaban14$17,076
LipitorAtorvastatin Calcium14$7,427
Rosuvastatin Calcium407$7,000
MyrbetriqMirabegron13$6,319
Levothyroxine Sodium286$4,190
Telmisartan119$3,589
Propranolol Hcl ErPropranolol Hcl23$3,071
Atorvastatin Calcium268$2,487
Amlodipine Besylate317$2,169
Valsartan66$1,914
Olmesartan Medoxomil59$1,911
Metoprolol Succinate131$1,910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lipitor$106$38,17350 claims
Novo NordiskOzempic$42$19,18412 claims
Johnson & JohnsonXarelto$67$17,07614 claims
Astellas Pharma US IncMyrbetriq$80$6,31913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in West Nyack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →